Dr Agarwals Health Care Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Healthcare Services | Market Cap: ₹16.5K Cr
Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from FY '22 to FY '24. Mature facilities are growing at around 18% CAGR, which is expected to continue over the next 2-3 years.
From Dr Agarwals Health Care Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹500
Market Cap
₹16.5K Cr
P/E Ratio
111.9
How does Dr Agarwals Health Care Ltd rank in Healthcare Services?
Compare Dr Agarwals Health Care Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Dr Agarwals Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹564 Cr, net profit ₹50 Cr.
Full financials →📊 Revenue & Sales Performance
- →Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from FY '22 to FY '24.
- →For the next 2-3 years, the company expects revenue growth from mature and new facilities combined to be around 20% annually.
- →Expansion is driven primarily by organic growth, with plans to open 8-10 new facilities per quarter and around 45-50 facilities per year.
- →Focus on core states: Tamil Nadu, Maharashtra, Karnataka, Andhra Pradesh, Telangana; with some expansion in northern regions like Gujarat, Jammu, Punjab.
- →Growth driven by increased footfall (6-7%), pricing increases (2-3%), and premiumization (6-7%).
- →Higher-end premium surgical procedures, such as cataract and refractive surgeries, with higher average ticket sizes (cataract ~INR 38,000; refractive ~INR 75,000-80,000), contribute significantly.
- →The overall eye-care market is projected to grow at 12-14% CAGR, with organized players currently serving 13-15% market share, indicating room for expansion.
📈 Profitability & Margins
- →Mature facilities are growing at around 18% CAGR, which is expected to continue over the next 2-3 years.
- →Overall company revenue growth, combining mature and new facilities, is guided at approximately 20% CAGR for the next 2-3 years.
- →EBITDA margins are expected to sustain at current levels despite ongoing expansion and new facility openings.
- →The company plans to open around 45-50 new facilities annually, supporting growth.
- →PAT grew by 25% in Q3 FY25 with margin improvements; this positive trend is expected to continue.
- →Earnings per share (EPS) growth implied through PAT growth and margin stability; no explicit EPS forecast was given, but strong revenue and profitability growth suggest progressive EPS improvement.
- →Management emphasizes continued operational strength and strategic execution fueling sustained growth in earnings.
🏗️ Capital Expenditure Plans
- →Focus remains predominantly on organic expansion, with plans to open 8-10 new facilities each quarter over the next few years.
- →Capex for primary (eye clinic) facilities ranges between INR 30-35 lakhs, with sizes between 750-1,500 sq ft.
- →Secondary facilities have a capex range of INR 4.5-7 crores, sized 4,000-7,000 sq ft (smaller in Mumbai).
- →No significant equity issuance has been done so far in acquisitions; acquisitions are primarily cash-based with deferred payments over 4 years.
- →Acquisitions are strategically targeted for entry into new markets (e.g., Delhi, UP, Punjab), with majority of growth in core markets via organic centers.
- →Example: Under-construction flagship tertiary hospital in Chennai, expected operational by early FY 2026.
- →Asset-light model with most facilities leased (220 out of 221), minimizing capital intensity.
- →No major expansion planned in Africa; focus is on stabilizing and moderate growth there.
💰 Fundraising & Capital Structure
- →There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript.
- →Regarding acquisitions, it is noted that so far all acquisitions have been through cash payouts, with no equity dilution involved.
- →The management has expressed an intention to explore combinations or mergers between listed entities within the next three years, which might involve share swaps, but details and timelines are still under consideration.
- →No concrete plans or information about raising fresh debt or equity capital have been disclosed during the call.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Dr Agarwals Health Care Ltd Q3 FY25 results?
Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from FY '22 to FY '24. Mature facilities are growing at around 18% CAGR, which is expected to continue over the next 2-3 years.
What is Dr Agarwals Health Care Ltd share price analysis?
Dr Agarwals Health Care Ltd currently shows a neutral. The stock trades at a P/E of 111.9 with a market cap of ₹16,519 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Agarwals Health Care Ltd planning capital expenditure?
Focus remains predominantly on organic expansion, with plans to open 8-10 new facilities each quarter over the next few years.
Keep Dr Agarwals Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.